Clinical Trials: Clinical Trial Operations & Compliance

Inventory Management in Clinical Trial Logistics

Posted on digi By digi

Inventory management in clinical trials goes beyond stock tracking—it ensures investigational medicinal products (IMPs), comparators, and ancillary supplies are available, reconciled, and compliant with regulatory expectations. For US sponsors, the FDA requires meticulous inventory records under 21 CFR Part 312. Poor inventory control can lead to stockouts, overages, and reconciliation gaps, each of which compromises patient safety, data integrity, and inspection readiness.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Monitoring CRO Performance: Regulatory Compliance Strategies

Posted on digi By digi

Contract Research Organizations (CROs) are widely used to support clinical trial operations, but ultimate responsibility for trial conduct rests with the sponsor. Under 21 CFR Part 312, sponsors are accountable for subject safety and data integrity, even when tasks are outsourced. The FDA, EMA, and ICH GCP guidelines emphasize the need for continuous oversight of CROs, with performance monitoring being a key requirement. Weak oversight results in frequent inspection findings, delayed submissions, and compromised trial credibility.

Click to read the full article.

Clinical Trial Operations & Compliance, Vendor Oversight & CRO Compliance

Vendor Contracts with CROs: Regulatory Compliance Essentials

Posted on digi By digi

Contracts between sponsors and Contract Research Organizations (CROs) are foundational to outsourced clinical trial operations. Under 21 CFR Part 312, sponsors remain accountable for trial conduct, even when tasks are delegated. The FDA, EMA, and ICH emphasize that contracts must clearly define responsibilities, oversight mechanisms, and regulatory compliance requirements. Weak or ambiguous contracts have been cited in numerous inspections as root causes of compliance failures. WHO also underscores that well-structured contracts are essential for safeguarding patient safety and ensuring trial data integrity in multi-country research.

Click to read the full article.

Clinical Trial Operations & Compliance, Vendor Oversight & CRO Compliance

Chain of Custody in Clinical Trial Logistics

Posted on digi By digi

Chain of custody (CoC) refers to the documented and unbroken trail showing the movement and handling of investigational medicinal products (IMPs) from manufacturer to depot, site, and ultimately the patient. For US sponsors, the FDA requires that every transfer of custody is recorded, ensuring accountability, product integrity, and patient safety. Inadequate custody documentation can result in Form 483s, warning letters, and, in some cases, trial suspension.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Ensuring Data Integrity in CRO Operations

Posted on digi By digi

Data integrity is a cornerstone of clinical trial compliance. When trial functions are outsourced to Contract Research Organizations (CROs), sponsors remain accountable for ensuring data reliability under 21 CFR Part 312. FDA inspections repeatedly cite deficiencies in CRO data integrity, including incomplete audit trails, poor source data verification, and delayed SAE reporting. ICH E6(R2), EMA guidance, and WHO GCP frameworks reinforce the sponsor’s obligation to oversee vendor data practices. Failure to ensure CRO data integrity can result in regulatory action, delayed submissions, or rejection of clinical data.

Click to read the full article.

Clinical Trial Operations & Compliance, Vendor Oversight & CRO Compliance

Risk Management in CRO Oversight for Clinical Trials

Posted on digi By digi

Outsourcing to Contract Research Organizations (CROs) is a standard practice in clinical trials. While this enables sponsors to access specialized expertise and resources, it also introduces significant compliance and operational risks. Under 21 CFR Part 312, the FDA makes it clear that sponsors remain ultimately accountable for trial conduct, regardless of CRO involvement. Risk management is therefore critical to ensuring compliance, protecting subject safety, and safeguarding data integrity. EMA, ICH GCP (E6[R2]), and WHO guidelines similarly require sponsors to apply structured, risk-based approaches when overseeing vendors.

Click to read the full article.

Clinical Trial Operations & Compliance, Vendor Oversight & CRO Compliance

Labeling Compliance in Clinical Trial Logistics

Posted on digi By digi

Labeling is a high-risk compliance area in clinical trial logistics. Incorrect or incomplete labels can compromise blinding, patient safety, and regulatory approval. For US sponsors, the FDA requires investigational products (IMPs) to be labeled in accordance with 21 CFR Part 312 and 21 CFR Part 211. Beyond FDA, EMA GDP, ICH GCP, and WHO guidelines also impose strict labeling requirements. Errors in trial labeling frequently result in FDA Form 483 observations and trial delays.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Import/Export Compliance in Clinical Trial Logistics

Posted on digi By digi

Clinical trial logistics frequently require cross-border shipments of investigational medicinal products (IMPs), comparators, and ancillary supplies. Each movement involves customs clearance, regulatory permits, and strict documentation. For US sponsors, failure to comply with import/export requirements can lead to shipment delays, trial suspension, and FDA citations under 21 CFR Part 312. Compliance failures also risk patient safety and data integrity when dosing schedules are interrupted.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Temperature Monitoring in Clinical Trial Logistics

Posted on digi By digi

Temperature monitoring ensures investigational medicinal products (IMPs) remain within approved storage and transport conditions from manufacture to patient administration. For US sponsors, failure to maintain adequate monitoring is a common cause of Form 483s and trial delays. FDA requires sponsors to ensure that temperature-sensitive drugs, particularly biologics, are stored and shipped within validated ranges. Deviations can compromise patient safety and data integrity.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Comparator Sourcing in Clinical Trial Logistics

Posted on digi By digi

Comparator sourcing is one of the most complex aspects of clinical trial logistics. Comparators—commercially available drugs used for comparison with investigational products (IMPs)—are essential in demonstrating efficacy and safety in randomized controlled trials. For US sponsors, FDA oversight of comparator sourcing ensures the authenticity, quality, and regulatory compliance of the comparator supply chain. Failures in comparator sourcing can result in delayed trial initiation, regulatory citations, and jeopardized trial outcomes.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance